Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Firms / Oxford Bioscience III Corporation

Oxford Bioscience III Corporation

Micro VC · probableNewton, MAoxbio.comSEC exempt reporting adviserone firm, 2 filing advisers

This firm files as 2 advisers on oxbio.com: Oxford Bioscience V Corporation. Each keeps its own CRD, funds and filings; the grouping is the website each swore to on Form ADV and is recomputed every pass.

Rasakan sensasi BIGSLOT288! Kesan menantang dalam permainan game digital online penuh kemenangan siap menguji nyalimu. Klik & buktikan kehebatanmu sekarang!

venture manager, reported GAV $20.6M across 2 vehicles

Importance
22
moderate
Active deployment
0
low
Emerging
0
low
Completeness
44
elevated
Freshness
100
high
Research priority
6
low
Identity and regulatory footprint
Headquarters
Newton, MAadviserinfo.sec.gov
Office address
55 CLEARWATER ROAD, Newton, MA, 02462adviserinfo.sec.gov
Business phone
617-357-7474adviserinfo.sec.gov
Website
HTTP://WWW.OXBIO.COM
SEC adviser type
exempt reporting adviseradviserinfo.sec.gov
SEC exemption claimed
unknown
Latest Form ADV
Jan 2, 2018
Private funds reported
4 (4 venture capital funds)adviserinfo.sec.gov
Private fund gross assets
$41.5Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
business phone
617-357-7474adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
no observed deals yet
Stated (the firm’s website)
Sectors
media
Stages
not stated or not yet read
Geography
australia, canada, france, germany, japan, singapore, united states
Check size
not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors: no observed deals yet
lead rate n/afollow-on rate n/anew logos, 12 months 0
Funds and vehicles
2 reported, 10 no longer reported
VehicleTypeVintageLifecycleReported GAVOwnersForm D soldLatest Form D
Oxford Bioscience Partners IV L.P.FundunknownUnknown$20.4M
Jan 2, 2018
75unknownunknown
Mrna Fund II L.P.FundunknownUnknown$192,914
Jan 2, 2018
64unknownunknown
Korea-Seoul Life Science FundFundunknownWound down$68.0M
Mar 24, 2015
7unknownunknown
Oxford Bioscience Partners II L.P.FundunknownWound down$5.3M
Mar 24, 2015
25unknownunknown
Oxford Bioscience Partners III L.P.FundunknownWound down$5.1M
Mar 24, 2015
39unknownunknown
Oxford Bioscience Partners (bermuda) II Limited PartnershipFundunknownWound down$4.1M
Mar 24, 2015
28unknownunknown
Oxford Bioscience Partners (gs-Adjunct) II L.P.FundunknownWound down$2.2M
Mar 24, 2015
3unknownunknown
Oxford Bioscience Partners (adjunct) II L.P.FundunknownWound down$1.1M
Mar 24, 2015
2unknownunknown
Oxford Bioscience Partners II Annex L.P.Continuation vehicleunknownWound down$957,756
Mar 24, 2015
24unknownunknown
Oxford Bioscience Partners (bermuda) III Limited PartnershipFundunknownWound down$754,523
Mar 24, 2015
11unknownunknown
Oxford Bioscience Partners (adjunct) III L.P.FundunknownWound down$308,609
Mar 24, 2015
2unknownunknown
Mrna Fund L.P.FundunknownWound down$68,050
Mar 24, 2015
21unknownunknown
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
2 current, 4 departed
Jonathan Jedidiah Fleming
President, Treasurer And Secretary · since Jul 1, 1999
Founder or executive
FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Matthew a Gibbs
Secretary · since Sep 1, 2015
Platform and operations
FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
4 departed (kept with end dates)
Investments on record
0 edges, 0 companies, 0 partner-attributed
No investment on record yet. Edges arrive from the firm’s portfolio page, financing announcements, and Form D board seats.
Co-investors
0 relationships from shared deals, counted for the whole firm
No co-investor relationship yet: these are derived only from rounds and portfolio listings the graph has seen both investors on.
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
31 dated events
  1. Sep 15, 2026
    Oxford Bioscience III Corporation: INSTITUTIONAL_VC -> MICRO_VC (venture manager, reported GAV $20.6M across 2 vehicles)
    Classification changedClassificationInferenceno URL
  2. Feb 27, 2017
    Cornelius T. Ryan (Senior Vice President) no longer on Schedule A of Oxford Bioscience III Corporation
    Person leftPeopleInferenceCornelius T. RyanSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  3. Mar 3, 2016
    Alan G. Walton (Chairman) no longer on Schedule A of Oxford Bioscience III Corporation
    Person leftPeopleInferenceAlan G. WaltonSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  4. Mar 3, 2016
    Edmund M. Olivier de Vesin (Senior Vice President) no longer on Schedule A of Oxford Bioscience III Corporation
    Person leftPeopleInferenceEdmund M. Olivier de VesinSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  5. Mar 3, 2016
    Oxford Bioscience Partners II Annex L.P. no longer reported on Form ADV by Oxford Bioscience III Corporation
    Fund no longer reportedFundsInferenceOxford Bioscience Partners II Annex L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  6. Mar 3, 2016
    Oxford Bioscience Partners (bermuda) III Limited Partnership no longer reported on Form ADV by Oxford Bioscience III Corporation
    Fund no longer reportedFundsInferenceOxford Bioscience Partners (bermuda) III Limited PartnershipSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  7. Mar 3, 2016
    Mrna Fund L.P. no longer reported on Form ADV by Oxford Bioscience III Corporation
    Fund no longer reportedFundsInferenceMrna Fund L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  8. Mar 3, 2016
    Oxford Bioscience Partners (adjunct) III L.P. no longer reported on Form ADV by Oxford Bioscience III Corporation
    Fund no longer reportedFundsInferenceOxford Bioscience Partners (adjunct) III L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  9. Mar 3, 2016
    Oxford Bioscience Partners (adjunct) II L.P. no longer reported on Form ADV by Oxford Bioscience III Corporation
    Fund no longer reportedFundsInferenceOxford Bioscience Partners (adjunct) II L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  10. Mar 3, 2016
    Oxford Bioscience Partners (bermuda) II Limited Partnership no longer reported on Form ADV by Oxford Bioscience III Corporation
    Fund no longer reportedFundsInferenceOxford Bioscience Partners (bermuda) II Limited PartnershipSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  11. Mar 3, 2016
    Oxford Bioscience Partners (gs-Adjunct) II L.P. no longer reported on Form ADV by Oxford Bioscience III Corporation
    Fund no longer reportedFundsInferenceOxford Bioscience Partners (gs-Adjunct) II L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  12. Mar 3, 2016
    Korea-Seoul Life Science Fund no longer reported on Form ADV by Oxford Bioscience III Corporation
    Fund no longer reportedFundsInferenceKorea-Seoul Life Science FundSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  13. Mar 3, 2016
    Oxford Bioscience Partners II L.P. no longer reported on Form ADV by Oxford Bioscience III Corporation
    Fund no longer reportedFundsInferenceOxford Bioscience Partners II L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  14. Mar 3, 2016
    Oxford Bioscience Partners III L.P. no longer reported on Form ADV by Oxford Bioscience III Corporation
    Fund no longer reportedFundsInferenceOxford Bioscience Partners III L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  15. Sep 1, 2015
    Matthew a Gibbs joined Schedule A of Oxford Bioscience III Corporation as Secretary
    Person joinedPeopleFactMatthew a GibbsSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  16. Mar 28, 2014
    Raymond N Charest (Assistant Secretary And Cfo) no longer on Schedule A of Oxford Bioscience III Corporation
    Person leftPeopleInferenceRaymond N CharestSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  17. Mar 30, 2012
    Oxford Bioscience Partners II Annex L.P. first reported on Form ADV by Oxford Bioscience III Corporation (Venture Capital Fund), GAV $2,566,154
    Fund first reported on Form ADVFundsFactOxford Bioscience Partners II Annex L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  18. Mar 30, 2012
    Oxford Bioscience Partners V L.P. first reported on Form ADV by Oxford Bioscience III Corporation (Venture Capital Fund), GAV $114,132,710
    Fund first reported on Form ADVFundsFactOxford Bioscience Partners V L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  19. Mar 30, 2012
    Oxford Bioscience Partners III L.P. first reported on Form ADV by Oxford Bioscience III Corporation (Venture Capital Fund), GAV $3,835,484
    Fund first reported on Form ADVFundsFactOxford Bioscience Partners III L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  20. Mar 30, 2012
    Mrna Fund V L.P. first reported on Form ADV by Oxford Bioscience III Corporation (Venture Capital Fund), GAV $2,617,706
    Fund first reported on Form ADVFundsFactMrna Fund V L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  21. Mar 30, 2012
    Oxford Bioscience III Corporation first filed Form ADV (ERA, venture capital fund adviser exemption)
    First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  22. Mar 30, 2012
    Oxford Bioscience Partners II L.P. first reported on Form ADV by Oxford Bioscience III Corporation (Venture Capital Fund), GAV $13,016,225
    Fund first reported on Form ADVFundsFactOxford Bioscience Partners II L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  23. Mar 30, 2012
    Oxford Bioscience Partners (adjunct) II L.P. first reported on Form ADV by Oxford Bioscience III Corporation (Venture Capital Fund), GAV $2,495,672
    Fund first reported on Form ADVFundsFactOxford Bioscience Partners (adjunct) II L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  24. Mar 30, 2012
    Oxford Bioscience Partners (bermuda) II Limited Partnership first reported on Form ADV by Oxford Bioscience III Corporation (Venture Capital Fund), GAV $9,575,121
    Fund first reported on Form ADVFundsFactOxford Bioscience Partners (bermuda) II Limited PartnershipSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  25. Mar 30, 2012
    Oxford Bioscience Partners (bermuda) III Limited Partnership first reported on Form ADV by Oxford Bioscience III Corporation (Venture Capital Fund), GAV $654,662
    Fund first reported on Form ADVFundsFactOxford Bioscience Partners (bermuda) III Limited PartnershipSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  26. Mar 30, 2012
    Oxford Bioscience Partners (adjunct) III L.P. first reported on Form ADV by Oxford Bioscience III Corporation (Venture Capital Fund), GAV $217,551
    Fund first reported on Form ADVFundsFactOxford Bioscience Partners (adjunct) III L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  27. Mar 30, 2012
    Korea-Seoul Life Science Fund first reported on Form ADV by Oxford Bioscience III Corporation (Venture Capital Fund), GAV $63,991,158
    Fund first reported on Form ADVFundsFactKorea-Seoul Life Science FundSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  28. Mar 30, 2012
    Oxford Bioscience Partners (gs-Adjunct) II L.P. first reported on Form ADV by Oxford Bioscience III Corporation (Venture Capital Fund), GAV $4,073,807
    Fund first reported on Form ADVFundsFactOxford Bioscience Partners (gs-Adjunct) II L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  29. Mar 30, 2012
    Mrna Fund L.P. first reported on Form ADV by Oxford Bioscience III Corporation (Venture Capital Fund), GAV $29,245
    Fund first reported on Form ADVFundsFactMrna Fund L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  30. Mar 30, 2012
    Mrna Fund II L.P. first reported on Form ADV by Oxford Bioscience III Corporation (Venture Capital Fund), GAV $1,046,802
    Fund first reported on Form ADVFundsFactMrna Fund II L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  31. Mar 30, 2012
    Oxford Bioscience Partners IV L.P. first reported on Form ADV by Oxford Bioscience III Corporation (Venture Capital Fund), GAV $95,897,035
    Fund first reported on Form ADVFundsFactOxford Bioscience Partners IV L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
  1. Sep 15, 2026
    Micro VC (probable, 80%, cls-1)
    venture manager, reported GAV $20.6M across 2 vehicles
  2. Sep 12, 2026
    Institutional venture firm (probable, 70%, cls-1)
    venture manager with no reported fund assets yet (scale unknown)
Evidence
28 observations from 2 sources
Every observation behind this profile, with its source, date and class
FactValueEffectiveClassSource
SEC adviser typeexempt_reporting_adviserJan 2, 2018FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
First Form ADV filing2012-03-30Jan 2, 2018FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Adv history loadedadv-hist-1Sep 12, 2026FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Latest Form ADV filing2018-01-02Jan 2, 2018FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Venture share of reported funds1Jan 2, 2018FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Business phone617-357-7474Jan 2, 2018FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
DescriptionRasakan sensasi BIGSLOT288! Kesan menantang dalam permainan game digital online penuh kemenangan siap menguji nyalimu. Klik & buktikan kehebatanmu sekarang!
“meta description”
Sep 14, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
HeadquartersNewton, MAJan 2, 2018FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Office address55 CLEARWATER ROAD, Newton, MA, 02462Jan 2, 2018FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Legal formCorporationJan 2, 2018FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Private funds reported4Jan 2, 2018FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Private fund gross assets (reported)$41.5MJan 2, 2018FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Stated geographyaustralia,canada,france,germany,japan,singapore,united states
“geography words on the home page”
Sep 14, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Stated sectorsmedia
“sector words on the home page”
Sep 14, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Venture funds reported4Jan 2, 2018FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
WebsiteHTTP://WWW.OXBIO.COMJan 2, 2018FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Website statusunreachable
“home page did not answer with HTML”
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Site titleBIGSLOT288 - Kesan Menantang Dalam Permainan Game Digital Online Penuh Kemenangan
“title tag”
Sep 14, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)